|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dermatologists should be familiar with BRAF-mutated conjunctival melanoma, which is usually located on the bulbar conjunctiva and associated with more frequent distant metastasis.
|
31361915 |
2020 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
|
31024839 |
2019 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A BRAF V600E mutation was detected in 42.6% of nevi and in 35.5% of CJM.
|
31247083 |
2019 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conjunctival melanoma requires investigation into the BRAF mutation in the case of a locally advanced tumor.
|
31418658 |
2019 |
|
Malignant melanoma of conjunctiva
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
|
27893585 |
2017 |
|
Malignant melanoma of conjunctiva
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both BRAF inhibitors suppressed growth of both <i>BRAF</i> mutant CM cell lines, but only one induced cell death.
|
28938534 |
2017 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A further aim was to determine the prevalence of BRAF mutations in conjunctival melanoma, to determine whether BRAF mutations are early events in pathogenesis, and relate clinicopathological features and prognosis to BRAF-mutation status.
|
27192168 |
2016 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutations were identified as early events in conjunctival melanoma, associated with a distinct clinicopathological profile, similar to BRAF-mutated cutaneous melanoma.
|
27009410 |
2016 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathological characteristics of BRAF-mutated CM have not been studied thoroughly.
|
26425792 |
2015 |
|
Malignant melanoma of conjunctiva
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytotoxicity, cell viability, proliferation, apoptosis rate and phosphorylation rate of ERK and Akt were analysed in three different conjunctival melanoma cell lines under the influence of the B-Raf inhibitor PLX 4720 at various concentrations.
|
26347528 |
2015 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The presence of NRAS or BRAF mutations in a mutually exclusive pattern in roughly half (47%) of conjunctival melanomas and the pattern of CNAs argue for conjunctival melanoma being closely related to cutaneous and mucosal melanoma but entirely distinct from uveal melanoma.
|
23633454 |
2013 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes.
|
21693616 |
2011 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To gain a better understanding of the molecular events leading to the development of conjunctival melanocytic lesions and conjunctival melanoma, this study was conducted to investigate the presence of T1799A BRAF oncogenic mutation in these lesions.
|
16123397 |
2005 |
|
Malignant melanoma of conjunctiva
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to determine whether the T1799A BRAF mutation found in cutaneous melanoma is also present in conjunctival melanoma.
|
15277467 |
2004 |